Navigation Links
Rubicon Filter

ProductsRubicon Filter
Company Rubicon Medical Corp.
Item Rubicon Filter
Features 
  • Filter is mounted on a standard 0.014'' guidewire
  • Unique design and small crossing profile allows one-step insertion and deployment of both filter and stent
  • Filter is deployed via a coaxial actuating wire at the proximal end of the guidewire
  • Filter basket is supported by floating Nitinol struts for superior apposition in vessel
  • 100 micron pore size is optimized for blood flow and capture efficiency
  • Compatible with 6F guide catheters
  • Large-bore catheter retrieval system is designed to minimize risk of debris loss during filter capture
  • Unique retrieval system actuator with graphics shows physician the exact status of the filter as it is being captured
Description The Rubicon Filter System is an embolic protection device that safely traps and removes much of the debris that may be dislodged during interventional procedures. The Rubicon Filter System comprises several components. The first is a guidewire-mounted filter, and the second is a capture catheter. Other ancillary components supplied with the system for convenience of use include an introducer, a syringe for flushing the capture catheter, and two torque devices.

The filter is mounted on a steerable 0.014" guidewire, which is designed to be compatible with devices delivered with a 0.014" guidewire. The coaxial actuating wire design eliminates the need for a delivery catheter, allowing a stent to be pre-loaded on the filter wire and delivered in a one-step insertion of both devices. The free-floating struts have three radiopaque markers and are designed to provide consistent apposition to tortuous vasculature. The distal tip is highly radiopaque and shapeable. When the procedure is completed, the capture catheter is telescoped over the filter and trapped debris, and then withdrawn. The capture catheter has a large bore sleeve designed to contain the collapsed filter and the debris trapped within it. The actuating device includes graphics that show the clinician the status of the filter throughout the retrieval process.

Info Rubicon Medical Corp.
Customer Service: (801) 886-9000
Web site:

Related medicine products :

1. Storz Fluid Filter - 0.2 micron
2. Storz Fluid Filter - 0.45 micron
3. Welch Allyn PanOptic Ophthalmoscope with Cobalt-Blue Filter and Corneal Viewing Lens
4. Lumicon Red Filter
5. Pocket Red Filter
6. Red Filter
7. Welch Allyn Binocular Indirect Ophthalmoscope with Diffuser Filter
8. Binocular Indirect Ophthalmoscope with Diffuser and Yellow Filter
9. Binocular Indirect Ophthalmoscope with Yellow Filter
10. Defiant 95% Bag Filter
11. FilterWire EZ Embolic Protection System
...any special order products are offered as 1-piece ...modular instruments may be customized with handles...ulation and flush ports. Many standard patterns ar...ations may affect delivery times. , Please Note: ...
...any special order products are offered as 1-piece ...modular instruments may be customized with handles...ulation and flush ports. Many standard patterns ar...ations may affect delivery times. , Please Note: ...
...any special order products are offered as 1-piece ...modular instruments may be customized with handles...ulation and flush ports. Many standard patterns ar...ations may affect delivery times. , Please Note: ...
The Featured Products are kept in stock at Mediflex and are offered as 1-piece or modular in regular or extra long lengths. All come equipped with insulation, flush ports, rotating shafts, ratchets (
Medicine Products:
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...clinical study carried out by Professor Ian Reed a... Zealand has found that the drug Zometa manufactur... than the drug Actonel produced by Procter and Gam...n which the bones breaks or becomes weak faster th...
...that using antiplatelet medication called clopidog...ces the risk of death from cardiovascular problems...per was published in the latest issue of JAMA. Dua...taneous coronary intervention using a combination ...
...in life are just taken for granted. But it turns o...lanations to such things are projected. One such e...ale and female voice.// An analysis of the brain s...evaluation of male and female voices found startli...
...ernment is supporting a programme named the "golde...together to validate medicine protocols //for the ...and Industrial Research, the Indian Council of Med...dian System of Medicines. Health Minister Anbumani...
Other Medicine News:Health News:Medicines Used In Antiplatelet Therapy Can Reduce Heart Attacks And Strokes 2Health News:Have You Ever Wondered Why Male And Female Voices Differ? 2
(Date:8/14/2008)... Aug. 14 /- Pharmasset, Inc...l company committed to,discovering, developing and...ions, reported unaudited financial results for the...set reported a net loss attributable to,common sto... $0.69 for the,quarter ended June 30, 2008, as com...
(Date:8/14/2008)...) Technology Evaluated to Enable Targeting and Inc...equencing, LEXINGTON, Mass. and HEIDELBERG, Germa...ional Genomics Research Institute (TGen) today ann...Gen will evaluate,Next-Generation-Sequencing equip...m(R) Microarray Technology., febit,s HybSelect(TM...
(Date:8/13/2008)... /- As biotechnology,pharm...y move clinical,trials beyond their own borders to...urope and South America, complicated regulatory en...siness, according to an analysis by,Aon Corporatio...ap provides,those companies a visual representatio...
(Date:8/13/2008)...no(TM) - proves the ability to automatically measu...g samples, SANTA CLARA, Calif., Aug. 13 /PRNewswi...ard: NWCI) a cardiac diagnostic and services compa...al validation study of QTinno(TM),(the "NCE3 Study...eading,cardiac safety expert with extensive experi...
Breaking Medicine Technology:Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 2Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 3Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 4Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 5Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 6Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 7Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 8Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 9febit and TGen Collaborate to Study New DNA Capture Method 2febit and TGen Collaborate to Study New DNA Capture Method 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4NewCardio Announces Positive Results From Third Clinical Validation Study 2NewCardio Announces Positive Results From Third Clinical Validation Study 3NewCardio Announces Positive Results From Third Clinical Validation Study 4NewCardio Announces Positive Results From Third Clinical Validation Study 5Researchers Create Protective Sac for Growing Stem Cells 15336 1Researchers Create Protective Sac for Growing Stem Cells 15336 2Kinetic Technologies Makers of Conquer 28R 29 Introduces New Website 15334 1ProActive Remedies LLC Announces Launch of New Allergy Medication 15332 1ProActive Remedies LLC Announces Launch of New Allergy Medication 15332 2Highmark Prominent Part of Pittsburgh City Skyline to Go Dark for One Hour to Support the Environment 15330 1Highmark Prominent Part of Pittsburgh City Skyline to Go Dark for One Hour to Support the Environment 15330 2
..., 2007 /PRNewswire-FirstCall/ -- Shire plc,announc...system),the first and only non-oral medication ap...ivity Disorder (ADHD) in children aged 6,to 12 yea...ntrol,and tolerability, according to results of a ...n Psychiatric Association (APA),annual meeting in ...
...hol Abuse Among ADHD Patients Nearly Triple That,o...llion People, INDIANAPOLIS, May 23, 2007 /PRNewswi... showed Strattera(R) (atomoxetine HCl),improved sy...r,(ADHD) in patients with comorbid alcohol abuse d... effectively with Strattera in,patients with both ...
Other Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 2Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 3Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 4Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 5Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 6